Estraderm, estradiol transdermal system, is designed to release estradiol through a rate-limiting membrane continuously upon application to intact skin.

Two systems are available to provide nominal in vivo delivery of 0.05 or 0.1 mg of estradiol per day via skin of average permeability (interindividual variation in skin permeability is approximately 20%). Each corresponding system having an active surface area of 10 or 20 cm² contains 4 or 8 mg of estradiol USP and 0.3 or 0.6 mL of alcohol USP, respectively. The composition of the systems per unit area is identical.

INDICATIONS
Estraderm® (estradiol transdermal system) is indicated in:
•Treatment of moderate to severe vasomotor symptoms associated with the menopause.
•Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.
•Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.
•Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risks of osteoporosis and non-estrogen medications should be carefully considered.
The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.

DOSAGE
Initiation of Therapy
When estrogen is prescribed for a postmenopausal woman with a uterus, progestin should also be initiated to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin. Use of estrogen alone or in combination with a progestin, should be with the lowest effective dose and the shortest duration consistent with treatment goals and risks for the individual woman. Patients should be reevaluated periodically as clinically appropriate (e.g. 3-month to 6-month intervals) to determine whether treatment is still necessary .For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.

Estraderm is currently available in two dosage forms – 0.05 mg and 0.1 mg. Patients should be started at the lowest dose. The lowest effective dose of Estraderm has not been determined.
For treatment of moderate to severe vasomotor symptoms or moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause, initiate therapy with Estraderm 0.05 applied to the skin twice weekly.
Prophylactic therapy with Estraderm to prevent postmenopausal bone loss should be initiated with the 0.05 mg/day dosage as soon as possible after menopause. The dosage may be adjusted if necessary. Discontinuation of estrogen therapy may reestablish bone loss at a rate comparable to the immediate postmenopausal period.
In women not currently taking oral estrogens, treatment with Estraderm may be initiated at once. In women who are currently taking oral estrogen, treatment with Estraderm should be initiated 1 week after withdrawal of oral hormone therapy, or sooner if menopausal symptoms reappear in less than 1 week.

Therapeutic Regimen
Estraderm therapy may be given continuously in patients who do not have an intact uterus. In those patients with an intact uterus, Estraderm may be given on a cyclic schedule (e.g., 3 weeks on drug followed by 1 week off drug).

SIDE EFFECTS
The most commonly reported adverse reaction to Estraderm in clinical trials was redness and irritation at the application site. This occurred in about 17% of the women treated and caused approximately 2% to discontinue therapy. Reports of rash have been rare. There have also been rare reports of severe systemic allergic reactions.

The following additional adverse reactions have been reported with estrogens:
1.Genitourinary system. Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow; breakthrough bleeding; spotting; dysmenorrheal, increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in amount of cervical secretion; changes in cervical ectropion; ovarian cancer; endometrial hyperplasia; endometrial cancer.
2.Breasts. Tenderness, enlargement, pain, nipple discharge, galactorrhea; fibrocystic breast changes; breast cancer.
3.Cardiovascular. Deep and superficial venous thrombosis; pulmonary embolism; thrombophlebitis; myocardial infarction; stroke; increase in blood pressure.
4.Gastrointestinal. Nausea, vomiting; abdominal cramps, bloating; cholestatic jaundice; increased incidence of gall bladder disease; pancreatitis, enlargement of hepatic hemangiomas.
5.Skin. Chloasma or melasma, which may persist when drug is discontinued; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair; hirsutism; pruritus, rash.
6.Eyes. Retinal vascular thrombosis; intolerance to contact lenses.
7.Central nervous system. Headache; migraine; dizziness; mental depression; chorea; nervousness; mood disturbances; irritability; exacerbation of epilepsy, dementia.
8.Miscellaneous. Increase or decrease in weight; reduced carbohydrate tolerance; aggravation of porphyria; edema; arthralgias; leg cramps; changes in libido; anaphylactoid/anaphylactic reactions including urticaria and angioedema; hypocalcemia; exacerbation of asthma; increased triglycerides.

本品是一种胶原蛋白水晶等离子女性荷尔蒙，通过高透皮技术
 
——产品显著作用：
1、有深度睡眠、睡眠时间延长
2、调整月经量、推迟绝经
3、塑身、代谢脂肪
4、使皮肤光洁、润泽、皱纹明显减少
5、使下垂乳房饱满、肌肉组织增加、制止乳房萎缩
6、减轻妇科炎症、老年性阴道炎、阴唇萎缩，使分泌物增多、增加阴道弹性
7、明显改善潮热、盗汗、胸闷、气短，精神倦怠、烦躁易怒情绪
8、有效改善更年期心慌、二连率心跳，降低心血管发病率
9、改善内分泌紊乱现象
 ——使用注意事项：
以下情况不可以使用：
◆ 患有或患过乳腺癌
◆ 患有依赖激素的肿瘤
◆ 曾出现过静脉血栓或肺部血块
◆ 近期出现过中风，胸痛或心肌梗塞
◆ 阴道不明原因出血
◆ 患有肝病或曾患肝病且肝功能尚未恢复者
◆ 使用Estraderm有过敏性反应
 
——使用方法：
◆ Estraderm贴膏为无棱小正方形，一疗程四周，每三天到四天换一次贴膜。若要使用第二疗程，应与第一疗程连续在一起，效

果更佳。
◆ 将贴膜贴于下腹，避免贴于腰上。不可贴于胸部。
◆ 换药时可将贴膜贴于下腹的其他部位，以保证每次贴过贴膜的部位最少空一周。
◆ 贴膜贴前皮肤需：干净、干燥、凉爽，不可擦粉、油、乳液等，无伤口和发炎部分。
◆ 每个贴膜都使用独立包装，按槽印撕破封套，取出贴膜。
◆ 将贴膜带有保护膜的一面对向您，将已显露的粘性部分贴于皮肤上，用手压住贴好的贴膜至少10秒种。
◆ 只要黏贴得当，洗浴，游泳，运动不会对贴膏产生影响。如若在此过程中脱落，请在擦干身上水渍后立即更换新贴膜。

——如何保存：冰箱保存（2到8摄氏度）。低于25摄氏度时最长可保存12个月。

------------------------------------------------------
详细处方信息以本药内容附件PDF文件（20101908432516.pdf）的“原文Priscribing Information”为准
------------------------------------------------------